Skip to main content
    D

    DaVita HealthCare Partners Inc (DVA)

    Official site

    HEALTHCARE • MEDICAL CARE FACILITIES • NYSE

    $174.14
    -0.42 (-0.24%)

    Market Cap: $10.98B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    DaVita HealthCare Partners Inc (DVA) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    DaVita HealthCare Partners (DVA) is expected to report earnings on Feb 1, 2027. In the quarter ended Sep 30, 2026, DaVita HealthCare Partners reported EPS of $3.82, above the $3.78 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    65%(26/40)
    Avg Surprise
    +6.28%
    Streak
    4 Q

    Upcoming Estimates

    Reports Feb 1, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$4.19
    Range$3.92 - $4.56
    8 analysts
    Revenue Consensus
    $3.69B
    Range$3.56B - $3.86B
    7 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$3.30
    Range$3.15 - $3.53
    3 analysts
    EPS Revisions
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$3.26+1.3%
    60d ago$3.33-0.9%
    30d ago$3.31-0.1%
    7d ago$3.30+0.1%
    Current$3.30
    Revenue Consensus
    $3.52B
    Range$3.51B - $3.54B
    2 analysts

    Next Report

    DVA has an expected report date of Feb 1, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 23.2% above the $3.40 reported for the quarter ended Dec 31, 2025.

    DVA Earnings Call

    The latest DVA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, DVA beat 26, missed 12 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $3.58B, up 4.7% from $3.42B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$3.82$3.78$3.39 - $4.02+1.06%Beat+52.2%71 up, 0 downOct 29, 2026$3.58B
    Jun 30, 2026$4.02$4.01$3.62 - $4.22+0.25%Beat+36.3%63 up, 2 downAug 4, 2026$3.55B
    Mar 31, 2026$2.87$2.33$2.22 - $2.46+23.18%Beat+43.5%61 up, 0 downMay 5, 2026$3.42B
    Dec 31, 2025$3.40$3.19$3.00 - $3.37+6.58%Beat+51.8%66 up, 0 downFeb 2, 2026$3.62B
    Sep 30, 2025$2.51$3.17$3.10 - $3.25-20.82%Miss-3.1%60 up, 2 downOct 29, 2025$3.42B
    Jun 30, 2025$2.95$2.75$2.67 - $2.84+7.27%Beat+13.9%50 up, 1 downAug 5, 2025$3.38B
    Mar 31, 2025$2.00$2.02$1.83 - $2.25-0.99%Miss-16.0%41 up, 2 downMay 12, 2025$3.22B
    Dec 31, 2024$2.24$2.13$2.07 - $2.31+5.16%Beat+19.8%53 up, 2 downFeb 13, 2025$3.29B
    Sep 30, 2024$2.59$2.72$2.61 - $2.85-4.78%Miss-9.1%30 up, 0 downOct 29, 2024$3.26B
    Jun 30, 2024$2.59$2.63$2.42 - $2.75-1.52%Miss+24.5%41 up, 0 downAug 6, 2024$3.19B
    Mar 31, 2024$2.38$1.92$1.86 - $2.07+23.96%Beat+50.6%41 up, 0 downMay 2, 2024$3.07B
    Dec 31, 2023$1.87$1.66$1.42 - $1.69+12.65%Beat+216.9%30 up, 0 downFeb 13, 2024$3.15B
    Sep 30, 2023$2.85$2.04$1.85 - $2.21+39.71%Beat+96.6%30 up, 0 downNov 7, 2023$3.12B
    Jun 30, 2023$2.08$1.74$1.55 - $1.93+19.54%Beat-9.6%31 up, 0 downAug 3, 2023$3.00B
    Mar 31, 2023$1.58$1.22$1.02 - $1.28+29.51%Beat-1.9%40 up, 0 downMay 8, 2023$2.87B
    Dec 31, 2022$0.59$0.91$0.73 - $1.00-35.16%Miss-70.8%40 up, 0 downFeb 22, 2023$2.92B
    Sep 30, 2022$1.45$1.76$1.60 - $1.98-17.61%Miss-38.6%61 up, 0 downOct 28, 2022$2.95B
    Jun 30, 2022$2.30$2.08$1.98 - $2.17+10.58%Beat-12.9%50 up, 0 downAug 1, 2022$2.93B
    Mar 31, 2022$1.61$1.87$1.77 - $1.96-13.90%Miss-23.0%50 up, 0 downMay 5, 2022$2.82B
    Dec 31, 2021$2.02$1.80$1.66 - $1.93+12.22%Beat+21.0%70 up, 0 downFeb 10, 2022$2.94B
    Sep 30, 2021$2.36$2.26$2.18 - $2.37+4.42%Beat+31.1%6N/AOct 28, 2021$2.94B
    Jun 30, 2021$2.64$2.17$2.11 - $2.25+21.66%Beat+35.4%7N/AAug 3, 2021$2.92B
    Mar 31, 2021$2.09$1.79$1.65 - $1.95+16.76%Beat+14.2%7N/AApr 29, 2021$2.82B
    Dec 31, 2020$1.67$1.87$1.61 - $1.96-10.70%Miss-10.2%10N/AFeb 11, 2021$5.66B
    Sep 30, 2020$1.80$1.44$1.17 - $1.63+25.00%Beat+17.6%11N/AOct 29, 2020$2.92B
    Jun 30, 2020$1.95$1.30$1.19 - $1.37+50.00%Beat+59.8%10N/AJul 30, 2020$121.78M
    Mar 31, 2020$1.83$1.47$1.38 - $1.58+24.49%Beat+101.1%10N/AMay 5, 2020$2.84B
    Dec 31, 2019$1.86$1.66$1.42 - $1.75+12.05%Beat+106.7%12N/AFeb 10, 2020$2.90B
    Sep 30, 2019$1.53$1.24$1.12 - $1.38+23.39%Beat+173.2%12N/ANov 5, 2019$2.90B
    Jun 30, 2019$1.22$1.11$0.98 - $1.46+9.91%Beat+16.2%12N/AAug 1, 2019$2.84B
    Mar 31, 2019$0.91$0.93$0.89 - $1.02-2.15%Miss-13.3%11N/AMay 7, 2019$2.74B
    Dec 31, 2018$0.90$0.90$0.77 - $0.990.00%In line-2.2%11N/AFeb 13, 2019$2.82B
    Sep 30, 2018$0.56$0.88$0.79 - $0.92-36.36%Miss-30.9%8N/ANov 7, 2018$2.85B
    Jun 30, 2018$1.05$0.97$0.86 - $1.05+8.25%Beat+14.1%9N/AAug 1, 2018$2.89B
    Mar 31, 2018$1.05$0.92$0.88 - $0.95+14.13%Beat+32.9%6N/AMay 3, 2018$2.85B
    Dec 31, 2017$0.92$0.92$0.89 - $1.100.00%In line-6.1%9N/AFeb 13, 2018$2.93B
    Sep 30, 2017$0.81$0.94$0.88 - $0.99-13.83%Miss-14.7%10N/ANov 7, 2017$2.88B
    Jun 30, 2017$0.92$0.90$0.84 - $1.04+2.22%Beat-8.9%10N/AAug 1, 2017$2.81B
    Mar 31, 2017$0.79$0.81N/A-2.47%Miss-14.1%N/AN/AMay 2, 2017$2.74B
    Dec 31, 2016$0.98$0.91N/A+7.69%Beat-3.0%N/AN/AFeb 16, 2017N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $10.86, up 10.8% from the year before. It was $3.86 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$10.86+10.8%
    Dec 31, 2024$9.80+16.9%
    Dec 31, 2023$8.38+40.8%
    Dec 31, 2022$5.95-34.7%
    Dec 31, 2021$9.11+25.7%
    Dec 31, 2020$7.25+31.3%
    Dec 31, 2019$5.52+55.1%
    Dec 31, 2018$3.56+3.5%
    Dec 31, 2017$3.44-10.9%
    Dec 31, 2016$3.86N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,800 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,83410
    2026Q2Jun 30, 20264,72510
    2026Q1Mar 31, 20264,44510
    2025Q4Dec 31, 20255,59210
    2025Q3Sep 30, 20255,12310
    2025Q2Jun 30, 20256,09511
    2025Q1Mar 31, 20254,63210
    2024Q4Dec 31, 20246,9628

    2026Q3 Earnings Call

    Opening remarks

    Nic Eliason Group Vice President, Investor Relations Thank you, and welcome to our third quarter conference call. We appreciate your continued interest in our company. I'm Nic Eliason, Group Vice President of Investor Relations. Joining me today are Javier Rodriguez, our CEO, and Joel Ackerman, our CFO. Please note that during this call, we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For further details concerning these risks and uncertainties, please refer to our third quarter earnings press release and our SEC filings, including our most recent annual report on Form 10-K, all subsequent quarterly reports on Form 10-Q, and other subsequent filings that we make with the SEC. Our forward-looking statements are based on information currently available to us, and we do not intend or undertake any duty to update these statements, except as may be required by law. Additionally, we'd like to remind you that during this call, we will discuss some non-GAAP financial measures. A reconciliation of these non-GAAP measures to the most comparable GAAP financial measures is included in our earnings press release furnished to the SEC and available on our website. I will now turn the call over to Javier Rodriguez.

    Javier Rodriguez CEO Thank you, Nic. Good afternoon, everyone, and thank you for joining the call today. Once again, our teammates have delivered excellent care for our patients and solid results for our shareholders. We're seeing meaningful progress across our clinical strategy, with investments in innovation translating into better patient outcomes and stronger business performance. Our maturing Integrated Kidney Care business is a prime example, as it continues to deliver clinical performance for our patients while starting to demonstrate its economic potential. In the same spirit, our rollout of expanded HD dialyzers marks an exciting new chapter in how we're advancing kidney care. Today, I'll share more on these priorities, review our third quarter financial performance, provide our outlook for the remainder of the year, and briefly discuss policy. But first, as always, let's begin with our clinical highlight. Today, I will highlight our advancements in fluid management. We're often asked about the clinical drivers behind our recent mortality improvements, and fluid overload is one of those critical areas we target. Because kidney failure impairs the body's ability to shed fluid, managing fluid intake between treatments and safely removing excess fluid during dialysis requires constant vigilance from both patients and care teams. Left unmanaged, excess fluid places strain on the cardiovascular and pulmonary systems, contributing to high blood pressure, heart failure, and respiratory difficulties.

    Frequently Asked Questions About DVA

    When is DaVita HealthCare Partners's next earnings date?

    DaVita HealthCare Partners's next earnings report is expected for Feb 1, 2027.

    Did DVA beat earnings estimates last quarter?

    Yes. DaVita HealthCare Partners reported EPS of $3.82 for the quarter ended Sep 30, 2026, above the $3.78 estimate, a 1.06% surprise.

    What EPS do analysts expect from DVA next quarter?

    The consensus EPS estimate for DaVita HealthCare Partners for the quarter ending Dec 31, 2026 is $4.19 from 8 analysts, with estimates from $3.92 to $4.56.

    How often does DVA beat earnings estimates?

    DaVita HealthCare Partners beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +2.71%.